Study of Viral Transduction of Human Auditory Sensory Cells for the Development of Gene Therapy (TREATGENE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03996824 |
Recruitment Status :
Recruiting
First Posted : June 25, 2019
Last Update Posted : October 22, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Gene therapy is a promising strategy to treat hearing loss and vestibular disorders, and Associated adenovirus (AAV) is shown as a good viral vector for inner ear therapy in animal models.
This study aims to study in vitro viral transduction of AAV in human inner ear cells, collected during non-conservative surgeries for vestibular schwannoma.
Condition or disease | Intervention/treatment |
---|---|
Hearing Loss, Sensorineural | Other: Peroperative collect of inner ear cells |
Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Other |
Time Perspective: | Prospective |
Official Title: | Study of Viral Transduction of Human Auditory Sensory Cells for the Development of Gene Therapy |
Actual Study Start Date : | February 19, 2019 |
Estimated Primary Completion Date : | February 1, 2022 |
Estimated Study Completion Date : | February 1, 2022 |

Group/Cohort | Intervention/treatment |
---|---|
AAV viral transduction
Collection of inner ear cells during a non-conservative surgical approach (translabyrinthine or transotic).
|
Other: Peroperative collect of inner ear cells
After obtaining an informed consent during the preoperative medical visit, and if a non-conservative approach (translabyrinthine or transotic) is decided, the collect of inner ear cells will be performed during surgical approach. The sample will be collect in a sterile tube, and carried to the laboratory were it will be placed bon cell culture. |
- AAV transduction in inner ear cells [ Time Frame: 10 days ]The transduction will be measured with immunostaining techniques
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patient ≥ 18 years old
- Operative indication for a non-conservative resection of vestibular schwannoma, decided by the surgeon in accordance with the patient
- Informed consent obtained
- Patients with a french social protection (AME excluded)
Exclusion Criteria:
- Intravestibular or intra-cochlear extension of the tumor
- Pregnant woman
- Patient with administrative control
- Medical contra-indication

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03996824
Contact: Ghizlene Lahlou | 33 1 45688891 | ghizlene.lahlou@pasteur.fr | |
Contact: Saaid Safieddine | saaid.safieddine@pasteur.fr |
France | |
Hôpital de Bicêtre | Recruiting |
Le Kremlin-Bicêtre, Ile De France, France, 94270 | |
Contact: Jérôme Nevoux, MD jerome.nevoux@aphp.fr | |
Principal Investigator: Jérôme Nevoux, MD | |
Hôpital Pitié-Salpétrière | Recruiting |
Paris, Ile De France, France, 75015 | |
Contact: Yann Nguyen, MD yann.nguyen@aphp.fr | |
Principal Investigator: Yann Nguyen, MD |
Study Director: | Ghizlene Lahlou | Institut Pasteur |
Responsible Party: | Institut Pasteur |
ClinicalTrials.gov Identifier: | NCT03996824 |
Other Study ID Numbers: |
2017-081 |
First Posted: | June 25, 2019 Key Record Dates |
Last Update Posted: | October 22, 2020 |
Last Verified: | October 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Hearing Loss Hearing Loss, Sensorineural Hearing Disorders Ear Diseases |
Otorhinolaryngologic Diseases Sensation Disorders Neurologic Manifestations Nervous System Diseases |